INSANE: Pulse biosciences | Rare Historical Photos

This Little-Known Biotech Stock Just Hit a New 5-Year High

Pulse Biosciences (PLSE) just hit a new 5-year high and has strong technical momentum. Shares are up more than 100% over the past 52 weeks. Revenue is projected to surge 652.38% this year and 236.71% next. Analyst sentiment is mixed, with ratings from “Strong Buy” to “Strong Sell,” reflecting its...

Barchart · Jul 24

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter.

Benzinga · Sep 21, 2022

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

Benzinga · Aug 4, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers

Benzinga · Apr 20, 2022

Looking Into Pulse Biosciences's Return On Capital Employed

Pulse Biosciences (NASDAQ:PLSE) brought in sales totaling $844.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 7.94%, resulting in a loss of $15.42 million.

Benzinga · Apr 1, 2022

Earnings Outlook For Pulse Biosciences

Pulse Biosciences (NASDAQ:PLSE) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Pulse Biosciences will report an earnings per share (EPS) of $-0.51.

Benzinga · Mar 30, 2022